Please assess the completion status of the following clinical trial:

Trial Title: S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis\* of 1 of the following by radiological features and clinical presentation:~  * Bronchoalveolar carcinoma (BAC)~    * Diffuse or ground glass appearance~ * Adenocarcinoma with bronchoalveolar features~ * BAC with focal invasion NOTE: \*Histological confirmation (excluding fine needle aspiration or bronchial brushings or washings) is required after the tumor tissue has been procured and the vaccine has been produced~* Selected stage IIIB (due to malignant pleural effusion) OR stage IV disease~* Measurable or nonmeasurable disease (e.g., diffuse infiltrative process) by CT scan of the chest both before and after tumor tissue procurement for vaccine~* Not a candidate for curative resection~* Tumor accessible for tissue procurement via thoracentesis or a surgical procedure~  * If a pleural effusion is the source of tumor tissue, at least 600 mL of fluid must be available for vaccine manufacture~ * Resection of brain metastases may be used for vaccine processing~    * Surgery must be done after study entry~* Asymptomatic previously treated (e.g., surgical resection or radiotherapy) brain metastases allowed provided the patient is neurologically stable~* No active or impending spinal cord compression or evidence of pericardial tamponade~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* Zubrod 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* CD4 count greater than 200/mm\^3~* No bleeding disorder~Hepatic~* Bilirubin no greater than 1.5 times upper limit of normal (ULN) (3 times ULN if liver metastases are present)~* SGOT or SGPT no greater than 2.5 times ULN (5 times ULN if liver metastases are present)~* Alkaline phosphatase no greater than 2.5 times ULN (5 times ULN if bone metastases are present)~Renal~* Not specified~Cardiovascular~* See Disease Characteristics~* Patients requiring surgery for tumor tissue procurement must meet the following criteria:~  * Pulmonary artery systolic pressure \< 40 mm Hg by echocardiogram\*~ * LVEF \> 40%~* No symptomatic congestive heart failure~* No thrombolic disorder~* No unstable angina pectoris~* No cardiac arrhythmia NOTE: \*Not needed if patient has no tricuspid regurgitation~Pulmonary~* No pulmonary hypertension~* No significant baseline hypoxia (i.e., O_2 saturation less than 90% OR requires greater than 2 L/min of supplemental O_2 via nasal cannula) by an oxygen saturation test~* No postobstructive pneumonia~* Patients requiring thoracoscopic surgery or thoracotomy for tumor tissue procurement must meet the following criteria:~  * Alveolar partial pressure of CO_2 \< 45 mm Hg~ * Predicted postresection FEV_1 ≥ 1.0 L~ * DLCO \> 50% of predicted~Immunologic~* No active immune or autoimmune disease~* No systemic lupus erythematosus~* No sarcoiditis~* No rheumatoid arthritis~* No glomerulonephritis~* No vasculitis~* No serious infection~* No hypersensitivity to any of the following:~  * Sargramostim (GM-CSF)~ * Pentastarch~ * Gentamicin~ * Human serum albumin~ * Dimethyl sulfoxide~ * Porcine trypsin~ * Fetal bovine serum~ * Recombinant benzonase~ * Other components of the vaccine or CG6444 adenoviral vector used in this study~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No poor nutritional status~* No psychiatric illness or social situation that would preclude study compliance or increase operative risk~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission~* No other concurrent uncontrolled illness~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 4 weeks since prior biologic therapy~* No prior gene therapy, including adenoviral-based therapy~Chemotherapy~* More than 4 weeks since prior chemotherapy~  * No prior regional chemotherapy administered through the pulmonary artery (if resection of the tumor in the treated lobe is planned)~Endocrine therapy~* More than 14 days since prior systemic corticosteroids~* No concurrent steroids~Radiotherapy~* See Disease Characteistics~* More than 4 weeks since prior radiotherapy~  * Disease must be outside the areas of prior radiotherapy OR clear progression at prior irradiated sites must be documented~* No prior radiotherapy to the tumor mass targeted for resection~Surgery~* See Disease Characteristics~* More than 7 days since prior surgery and recovered~Other~* More than 2 weeks since prior epidermal growth factor receptor inhibitors~* No other concurrent nonprotocol-specified treatment~* No concurrent immunosuppressants~* No concurrent chronic anticoagulation therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): GVAX lung cancer vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy